schliessen

Filtern

 

Bibliotheken

MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Recent studies provide convincing evidence that a combined immunohistochemical or fluorescence in situ hybridization (FISH) score of MYC, BCL2, BCL6 proteins and MYC translocations predicted outcome in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubic... Full description

Journal Title: PLoS ONE 2014, Vol.9(8)
Main Author: Yan, Li-Xu
Other Authors: Liu, Yan-Hui , Luo, Dong-Lan , Zhang, Fen , Cheng, Yu , Luo, Xin-Lan , Xu, Jie , Cheng, Jie , Zhuang, Heng-Guo
Format: Electronic Article Electronic Article
Language:
Subjects:
ID: E-ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0104068 ; PMCID: 4121314 ; PMID: 25090026
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: pubmed_central4121314
title: MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
format: Article
creator:
  • Yan, Li-Xu
  • Liu, Yan-Hui
  • Luo, Dong-Lan
  • Zhang, Fen
  • Cheng, Yu
  • Luo, Xin-Lan
  • Xu, Jie
  • Cheng, Jie
  • Zhuang, Heng-Guo
subjects:
  • Research Article
  • Medicine And Health Sciences
ispartof: PLoS ONE, 2014, Vol.9(8)
description: Recent studies provide convincing evidence that a combined immunohistochemical or fluorescence in situ hybridization (FISH) score of MYC, BCL2, BCL6 proteins and MYC translocations predicted outcome in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, by far, all these researches are based on Western populations. Therefore, we investigate the prognostic relevance of MYC-, BCL2- and BCL6-rearrangements and protein expression by immunohistochemistry and FISH from 336 de novo DLBCL, NOS treated with CHOP or R-CHOP. Breaks in MYC and BCL6 , and fusion in IGH/BCL2 were detected in 9.7%, 20.0%, and 11.1% of the cases, respectively, and were not significantly associated with clinical outcomes. Protein overexpression of MYC (≥40%), BCL2 (≥70%) and BCL6 (≥50%) was encountered in 51%, 51% and 36% of the tumors, respectively. On the basis of MYC, BCL2 and BCL6 expression, double-hit scores (DHSs) and triple-hit score (THS) were assigned to all patients with DLBCL. Patients with high MYC/BCL2 DHS, high MYC/BCL6 DHS and high THS had multiple adverse prognostic factors including high LDH level, poor performance status, advanced clinical stage, high International Prognostic Index (IPI) score, and non-germinal center B-cell. In univariate analysis, high MYC/BCL2 DHS, high MYC/BCL6 DHS and high THS were associated with inferior OS and PFS in both CHOP and R-CHOP cohorts ( P
language:
source:
identifier: E-ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0104068 ; PMCID: 4121314 ; PMID: 25090026
fulltext: fulltext
issn:
  • 1932-6203
  • 19326203
url: Link


@attributes
ID1322005288
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid4121314
sourceidpubmed_central
recordidTN_pubmed_central4121314
sourceformatXML
sourcesystemPC
pqid1551608408
galeid416975232
display
typearticle
titleMYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
creatorYan, Li-Xu ; Liu, Yan-Hui ; Luo, Dong-Lan ; Zhang, Fen ; Cheng, Yu ; Luo, Xin-Lan ; Xu, Jie ; Cheng, Jie ; Zhuang, Heng-Guo
contributorZhang, Luwen (editor)
ispartofPLoS ONE, 2014, Vol.9(8)
identifier
subjectResearch Article ; Medicine And Health Sciences
descriptionRecent studies provide convincing evidence that a combined immunohistochemical or fluorescence in situ hybridization (FISH) score of MYC, BCL2, BCL6 proteins and MYC translocations predicted outcome in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, by far, all these researches are based on Western populations. Therefore, we investigate the prognostic relevance of MYC-, BCL2- and BCL6-rearrangements and protein expression by immunohistochemistry and FISH from 336 de novo DLBCL, NOS treated with CHOP or R-CHOP. Breaks in MYC and BCL6 , and fusion in IGH/BCL2 were detected in 9.7%, 20.0%, and 11.1% of the cases, respectively, and were not significantly associated with clinical outcomes. Protein overexpression of MYC (≥40%), BCL2 (≥70%) and BCL6 (≥50%) was encountered in 51%, 51% and 36% of the tumors, respectively. On the basis of MYC, BCL2 and BCL6 expression, double-hit scores (DHSs) and triple-hit score (THS) were assigned to all patients with DLBCL. Patients with high MYC/BCL2 DHS, high MYC/BCL6 DHS and high THS had multiple adverse prognostic factors including high LDH level, poor performance status, advanced clinical stage, high International Prognostic Index (IPI) score, and non-germinal center B-cell. In univariate analysis, high MYC/BCL2 DHS, high MYC/BCL6 DHS and high THS were associated with inferior OS and PFS in both CHOP and R-CHOP cohorts ( P <0.05). The highly significant correlations with OS and PFS were maintained in multivariate models that controlled for IPI ( P <0.05). DLBCLs with high DHSs and high THS share the clinical features and poor prognosis of double-hit lymphoma ( P >0.05). These data together suggest that the immunohistochemical DHSs and THS defined a large subset of DLBCLs with double-hit biology and was strongly associated with poor outcome in patients treated with R-CHOP or CHOP.
source
version8
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Yan, Li-Xu
1Liu, Yan-Hui
2Luo, Dong-Lan
3Zhang, Fen
4Cheng, Yu
5Luo, Xin-Lan
6Xu, Jie
7Cheng, Jie
8Zhuang, Heng-Guo
9Zhang, Luwen
titleMYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
descriptionRecent studies provide convincing evidence that a combined immunohistochemical or fluorescence in situ hybridization (FISH) score of MYC, BCL2, BCL6 proteins and MYC translocations predicted outcome in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, by far, all these researches are based on Western populations. Therefore, we investigate the prognostic relevance of MYC-, BCL2- and BCL6-rearrangements and protein expression by immunohistochemistry and FISH from 336 de novo DLBCL, NOS treated with CHOP or R-CHOP. Breaks in MYC and BCL6 , and fusion in IGH/BCL2 were detected in 9.7%, 20.0%, and 11.1% of the cases, respectively, and were not significantly associated with clinical outcomes. Protein overexpression of MYC (≥40%), BCL2 (≥70%) and BCL6 (≥50%) was encountered in 51%, 51% and 36% of the tumors, respectively. On the basis of MYC, BCL2 and BCL6 expression, double-hit scores (DHSs) and triple-hit score (THS) were assigned to all patients with DLBCL. Patients with high MYC/BCL2 DHS, high MYC/BCL6 DHS and high THS had multiple adverse prognostic factors including high LDH level, poor performance status, advanced clinical stage, high International Prognostic Index (IPI) score, and non-germinal center B-cell. In univariate analysis, high MYC/BCL2 DHS, high MYC/BCL6 DHS and high THS were associated with inferior OS and PFS in both CHOP and R-CHOP cohorts ( P <0.05). The highly significant correlations with OS and PFS were maintained in multivariate models that controlled for IPI ( P <0.05). DLBCLs with high DHSs and high THS share the clinical features and poor prognosis of double-hit lymphoma ( P >0.05). These data together suggest that the immunohistochemical DHSs and THS defined a large subset of DLBCLs with double-hit biology and was strongly associated with poor outcome in patients treated with R-CHOP or CHOP.
subject
0Research Article
1Medicine and health sciences
general
025090026
14121314
210.1371/journal.pone.0104068
3PMC (PubMed Central)
sourceidpubmed_central
recordidpubmed_central4121314
issn
01932-6203
119326203
rsrctypearticle
creationdate2014
addtitlePLoS ONE
searchscopepubmed_central
scopepubmed_central
lsr30VSR-Enriched:[pages, galeid, pqid]
sort
titleMYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
authorYan, Li-Xu ; Liu, Yan-Hui ; Luo, Dong-Lan ; Zhang, Fen ; Cheng, Yu ; Luo, Xin-Lan ; Xu, Jie ; Cheng, Jie ; Zhuang, Heng-Guo
creationdate20140804
facets
frbrgroupid5813769630995813806
frbrtype5
creationdate2014
topic
0Research Article
1Medicine And Health Sciences
collectionPMC (PubMed Central)
prefilterarticles
rsrctypearticles
creatorcontrib
0Yan, Li-Xu
1Liu, Yan-Hui
2Luo, Dong-Lan
3Zhang, Fen
4Cheng, Yu
5Luo, Xin-Lan
6Xu, Jie
7Cheng, Jie
8Zhuang, Heng-Guo
9Zhang, Luwen
jtitlePlos One
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Yan
1Liu
2Luo
3Zhang
4Cheng
5Xu
6Zhuang
aufirst
0Li-Xu
1Yan-Hui
2Dong-Lan
3Fen
4Yu
5Xin-Lan
6Jie
7Heng-Guo
8Luwen
au
0Yan, Li-Xu
1Liu, Yan-Hui
2Luo, Dong-Lan
3Zhang, Fen
4Cheng, Yu
5Luo, Xin-Lan
6Xu, Jie
7Cheng, Jie
8Zhuang, Heng-Guo
9Zhang, Luwen
atitleMYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
jtitlePLoS ONE
risdate20140804
volume9
issue8
eissn1932-6203
formatjournal
genrearticle
ristypeJOUR
abstractRecent studies provide convincing evidence that a combined immunohistochemical or fluorescence in situ hybridization (FISH) score of MYC, BCL2, BCL6 proteins and MYC translocations predicted outcome in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, by far, all these researches are based on Western populations. Therefore, we investigate the prognostic relevance of MYC-, BCL2- and BCL6-rearrangements and protein expression by immunohistochemistry and FISH from 336 de novo DLBCL, NOS treated with CHOP or R-CHOP. Breaks in MYC and BCL6 , and fusion in IGH/BCL2 were detected in 9.7%, 20.0%, and 11.1% of the cases, respectively, and were not significantly associated with clinical outcomes. Protein overexpression of MYC (≥40%), BCL2 (≥70%) and BCL6 (≥50%) was encountered in 51%, 51% and 36% of the tumors, respectively. On the basis of MYC, BCL2 and BCL6 expression, double-hit scores (DHSs) and triple-hit score (THS) were assigned to all patients with DLBCL. Patients with high MYC/BCL2 DHS, high MYC/BCL6 DHS and high THS had multiple adverse prognostic factors including high LDH level, poor performance status, advanced clinical stage, high International Prognostic Index (IPI) score, and non-germinal center B-cell. In univariate analysis, high MYC/BCL2 DHS, high MYC/BCL6 DHS and high THS were associated with inferior OS and PFS in both CHOP and R-CHOP cohorts ( P <0.05). The highly significant correlations with OS and PFS were maintained in multivariate models that controlled for IPI ( P <0.05). DLBCLs with high DHSs and high THS share the clinical features and poor prognosis of double-hit lymphoma ( P >0.05). These data together suggest that the immunohistochemical DHSs and THS defined a large subset of DLBCLs with double-hit biology and was strongly associated with poor outcome in patients treated with R-CHOP or CHOP.
pubPublic Library of Science
doi10.1371/journal.pone.0104068
pmid25090026
pagese104068
oafree_for_read
date2014-08-04